Results 121 to 130 of about 3,987 (159)
Clinical relevance of CompEx Asthma and impact on disease trajectory: benralizumab effect. [PDF]
ERJ Open ResBolton C +7 more
europepmc +1 more source
Mirror, mirror on the wall: is CompEx the fairest endpoint of all? [PDF]
ERJ Open ResHung CT, Erickson SR, Wu CH.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Benralizumab for the treatment of asthma
Expert Review of Clinical Immunology, 2017Benralizumab is a humanized monoclonal antibody directed at the a subunit of the interleukin-5 receptor (IL-5R) that is under clinical development. The binding of benralizumab with the alpha chain of IL-5R results in inhibition of hetero-oligomerization of alpha and beta subunits and thus no signal transduction occurs.
Tara Saco, Amber N Pepper
exaly +7 more sources
Benralizumab as a potential treatment of asthma
Expert Opinion on Biological Therapy, 2017Current anti-inflammatory asthma therapies including inhaled corticosteroids and leukotriene modifiers, are not always able to appropriately control the disease and other approaches are needed. These therapies specific target IgE (omalizumab) or IL-5 (mepolizumab).
openaire +2 more sources
Benralizumab: First Global Approval
Drugs, 2018Kyowa Hakko Kirin, AstraZeneca and subsidiaries are developing benralizumab (Fasenra™)-a humanised anti-interleukin-5 receptor alpha chain (IL-5Rα) monoclonal antibody-as a treatment of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD).
openaire +2 more sources